Skip to main content

Table 2 Array CGH results (n = 31) in ESFT patient samples arranged by diagnosis.

From: Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors

Code

Diagnosis

Origin of sample

Array CGH results

Number of changes

CDKN2A

deletion status1

D150

Ewing

PRI

+1q, +2, +4, +6, +7, +8, -10, +12, -16q, +17, -19, +20

12

No deletion 2

D152

Ewing

PRI

+5, +7, +8, +21

4

No deletion 2

D153

Ewing

PRI

+1, -2q35-qter, +6, +8, +9p, -9q34.11, -10, +11q24.3-qter, +12, +16p, +19, +20q12-qter, +22q11.21-q12.1

13

No deletion 2

D154

Ewing

PRI

-3p13, -3p25.1-p25.3, -6q21, -6q24.1-q24.2, +8p11.21-p21.2, -8p21.3-pter, +8q, -9q, amp20q11.23, -20q11.23-q13.12, amp20q13.12-q13.2, +20q13.2-qter, -22q11.23, amp22q12.1-q12.1 (uncontinuous), +22q12.2-q12.3, -22q12.3-qter

16

No deletion 2

D155

Ewing

PRI

No changes detected

0

No deletion 2

D162

Ewing

PRI

-9p21.2-p21.3

1

Heterozygous deletion 2

D239

Ewing

PRI

No changes detected

0

No deletion 2

D240

Ewing

PRI

+1q22-qter, +12, +Xq26.3-qter

3

No deletion 2

D241

Ewing

PRI

No changes detected

0

No deletion 2

D245

Ewing

PRI

+4q25-qter, +5, +8, +13q11-q12.2

4

No deletion 2

D248

Ewing

PRI

+1, +2q21.2-q33.1, amp 2q31.2-q33.1, -2q33.2-qter, -4, +8, del 9p21.3, -10, +11q24.3-qter, +12, +14, -16p12.3, -16q, +17p, -17q, +22q11.21-q12.1

16

Homozygous deletion 2

D250

Ewing

PRI

-3q13.31-q22.3, del 9p21.3, -Xp11.3

3

Homozygous deletion 2

D311

Ewing

PRI

+1q22-qter, +8, -10p15.3, -16q, +17q21.31-qter, -19q13.43

6

No deletion 3

D313

Ewing

PRI

+2, +8

2

No deletion 3

D316

Ewing

PRI

+2, +8, +14q11.2-q13.2, -14q13.3-q21.1, +14q21.1-qter, -X

6

No deletion 3

D320

Ewing

PRI

+8

1

No deletion 3

D322

Ewing

PRI

+8, -16q, +19p

3

No deletion 3

D242

Ewing Extr

PRI

+1q

1

No deletion 2

D246

Ewing Extr

PRI

No changes detected

0

No deletion 2

D249

Ewing Extr

PRI

-1p34.3-pter, +3p22.1-pter, -6p11.2-p21.31, +8, -10q23.1, +10q25.1-qter, -13q13.3-q14.3, +13q21.1-q22.1, +15q21.3-q22.2, +19q13.31-qter, +20q13.33

11

No deletion 2

D252

Ewing Extr

PRI

+2, +5, +6, -7, +8, -9p21.3, +12, +14, +21, -X

10

Homozygous deletion 2

D253

Askin's

PRI

+8, -Y

2

No deletion 2

D254

Askin's

PRI

+2, +3, -4q34.3-qter, -5, +6, -7, -9, del 9p21.3, -10, +11q24.3-qter, +12, -13, +14, +16, +18, +19, +20, +21, +22q11.21-q12.1

19

Homozygous deletion 2

D157

Ewing

REC

+2p, +2q11.2-q22.3, -3q13.13-q13.33, +4q31.3-qter, +8, +12p, +12q12-q21.31, -16q, -17p, -19, +X

11

No deletion 2

D156

Askin's

REC

+1q, +8p11.21-p11.22, +8p23.1-pter, +8q, +11q12.3-q13.2, +12q13.2-q14.1, -16q, +19p

8

No deletion 2

D255

Ewing

MET

+1q, +2, +5, +6, +8, +12, +13, +15, -16, -17, +18, -19, +20, +21

14

No deletion 2

D256

Ewing

MET

-1q24.2-q25.3, +8

2

No deletion 3

D312

Ewing

MET

+1, +2p, +2q11.2-q21.3, -3, -4, -5q, +6p, +6q12, -6q13-qter, +7q, +8, +9, -10, -11p, -11q12.1-q24.2, +11q24.3-qter, +12, -13, +14, +15q15.2-qter, -16q, -17, -18, -19, +20, +X

26

No deletion 3

D321

Ewing

MET

+2, +5, +6, +8, +14, +15, -16q, -20p, +21, -Xp11.21-p11.22, -Xq

11

No deletion 3

D257

PNET

MET

+1p11.2-p13.2, +1p22.1-p32.3, +1p35.1-pter, +1q, -3p24.3-p25.1, +6q23.1-qter, +7, +8q, -9p, +9q22.1-q33.3, +12p, +12q12-q15

12

Heterozygous deletion 2

D315

PNET

MET

-7p, -9p21.1-p21.3, del 9p21.3, -16q, -22q12.1, -22q13.2-q13.32

6

Homozygous deletion 3

  1. 1 CDKN2A deletion was regarded as homozygous if the copy number log2 ratio was < -2.0 and as heterozygous if the ratio was -1.5 to -2.0. 2 CDKN2A deletion result published previously by Savola et al. [18] in an article, which included total of 26 ESFT patient samples. 3 CDKN2A deletion status not published before.
  2. Extr = extraskeletal; PRI = primary tumor; REC = local recurrence; MET = metastasis.